Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: Analysis of single-agent and combined modality approaches

Radiation Oncology

Volumn 6, Issue 1, 2011, Pages

  Beal, Kathryn ^a   Abrey, Lauren E ^a   Gutin, Philip H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CILENGITIDE; CORTICOSTEROID; CT 322; CYTOTOXIC AGENT; DASATINIB; ENZYME INDUCING ANTIEPILEPTIC AGENT; ETOPOSIDE; GADOLINIUM; IRINOTECAN; LOMUSTINE; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; TEMOZOLOMIDE; THALIDOMIDE; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN A; VATALANIB; XL 184; MONOCLONAL ANTIBODY;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTERIAL THROMBOEMBOLISM; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; CHEMORADIOTHERAPY; CONVULSION; DIGESTIVE SYSTEM PERFORATION; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GLIOBLASTOMA; HUMAN; HYPERTENSION; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; INTESTINE PERFORATION; LUNG EMBOLISM; LYMPHOCYTOPENIA; MEMORY DISORDER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; NEUROSURGERY; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALVAGE THERAPY; SIDE EFFECT; SYSTEMIC HEMORRHAGE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR RECURRENCE; VENOUS THROMBOEMBOLISM; WOUND HEALING; ADJUVANT THERAPY; BIOLOGICAL MODEL; BRAIN TUMOR; EVALUATION; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RECURRENT DISEASE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; COMBINED MODALITY THERAPY; GLIOBLASTOMA; HUMANS; MODELS, BIOLOGICAL; NEOADJUVANT THERAPY; RECURRENCE; SALVAGE THERAPY;

EID: 78650940726     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-6-2     Document Type: Review

References (114)

1. Maher EA, McKee AC. Neoplasms of the central nervous system. Atlas of diagnostic oncology 2003, 5-10. London: Elsevier Science, Skarin AT, Canellos GP, 3.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300. 10.3322/caac.20073, 20610543.
3. Central Brain Tumor Registry of the United States (CBTRUS) 2010 CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2006. Central Brain Tumor Registry of the United States (CBTRUS)., http://www.cbtrus.org/reports/reports.html
4. National Comprehensive Cancer Network clinical practice guidelines in oncology-central nervous system cancers. v.1.2010. , http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf
5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, . European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987-996. 10.1056/NEJMoa043330, 15758009, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group.
6. Wen PY, DeAngelis LM. Chemotherapy for low-grade gliomas: emerging consensus on its benefits. Neurology 2007, 68(21):1762-1763. 10.1212/01.wnl.0000266866.13748.a9, 17515537.
7. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999, 17(8):2572-2578.
8. Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J, . North American Brain Tumor Consortium A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol 2006, 8(2):189-193. 10.1215/15228517-2005-010, 1871932, 16533878, North American Brain Tumor Consortium.
9. Cloughesy TF, Filka E, Kuhn J, Nelson G, Kabbinavar F, Friedman H, Miller LL, Elfring GL. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 2003, 97(9 suppl):2381-2386. 10.1002/cncr.11306, 12712460.
10. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000, 83(5):588-593. 10.1054/bjoc.2000.1316, 2363506, 10944597.
11. Avastin® [package insert]. 2009, South San Francisco, CA: Genentech, Inc.
12. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD, McDonald DM. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004, 165(1):35-52. 1618540, 15215160.
13. Huang J, Frischer JS, Serur A, Kadenhe A, Yokoi A, McCrudden KW, New T, O'Toole K, Zabski S, Rudge JS, Holash J, Yancopoulos GD, Yamashiro DJ, Kandel JJ. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 2003, 100(13):7785-7790. 10.1073/pnas.1432908100, 164665, 12805568.
14. Chi A, Norden AD, Wen PY. Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev Anticancer Ther 2007, 7(11):1537-1560. 10.1586/14737140.7.11.1537, 18020923.
15. Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 2008, 7(12):1152-1160. 10.1016/S1474-4422(08)70260-6, 19007739.
16. Salmaggi A, Eoli M, Frigerio S, Silvani A, Gelati M, Corsini E, Broggi G, Boiardi A. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol 2003, 62(3):297-303. 10.1023/A:1023367223575, 12777082.
17. Takano S, Yoshii Y, Kondo S, Suzuki H, Maruno T, Shirai S, Nose T. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 1996, 56(9):2185-2190.
18. Nam DH, Park K, Suh YL, Kim JH. Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance. Oncol Rep 2004, 11(7):863-869.
19. Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, Hagedorn NL, McCarville MB, Stewart CF, Davidoff AM. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007, 13(13):3942-3950. 10.1158/1078-0432.CCR-07-0278, 17606728.
20. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006, 66(16):7843-7848. 10.1158/0008-5472.CAN-06-1010, 16912155.
21. Hu B, Guo P, Bar-Joseph I, Imanishi Y, Jarzynka MJ, Bogler O, Mikkelsen T, Hirose T, Nishikawa R, Cheng SY. Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway. Oncogene 2007, 26(38):5577-5586. 10.1038/sj.onc.1210348, 2846324, 17369861.
22. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD, Thurston G. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006, 444(7122):1032-1037. 10.1038/nature05355, 17183313.
23. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284(5422):1994-1998. 10.1126/science.284.5422.1994, 10373119.
24. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma [abstract]. Neuro Oncol 2005, 7(3):369.
25. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23):2335-2342. 10.1056/NEJMoa032691, 15175435.
26. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000, 18(4):708-715.
27. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7(9):987-989. 10.1038/nm0901-987, 11533692.
28. Vredenburgh JJ, Desjardins A, Herndon JE, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007, 13(4):1253-1259. 10.1158/1078-0432.CCR-06-2309, 17317837.
29. Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25(30):4722-4729. 10.1200/JCO.2007.12.2440, 17947719.
30. Desjardins A, Vredenburgh JJ, Reardon DA, Herndon JE, Marcello J, Peters K, Gururangan S, Sathornsumetee S, Rich JN, Friedman HS. Long-term survival from the initial trial of bevacizumab and irinotecan [abstract]. J Clin Oncol 2010, 28(15 suppl):191s.
31. Friedman HS, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27(28):4733-4740. 10.1200/JCO.2008.19.8721, 19720927.
32. Cloughesy T, Vredenburgh JJ, Day B, Das A, Friedman HS, . the BRAIN Investigators Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN stud [abstract]. J Clin Oncol 2010, 28(15 suppl):181s. the BRAIN Investigators.
33. Narayana A, Kelly P, Golfinos J, Parker E, Johnson G, Knopp E, Zagzag D, Fischer I, Raza S, Medabalmi P, Eagan P, Gruber ML. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 2009, 110(1):173-180. 10.3171/2008.4.17492, 18834263.
34. Poulsen HS, Grunnet K, Sorensen M, Olsen P, Hasselbalch B, Nelausen K, Kosteljanetz M, Lassen U. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol 2009, 48(1):52-58. 10.1080/02841860802537924, 19031176.
35. Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, Schultz L, Mikkelsen T. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 2009, 91(3):329-336. 10.1007/s11060-008-9718-y, 18953493.
36. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008, 70(10):779-787. 10.1212/01.wnl.0000304121.57857.38, 18316689.
37. Verhoeff JJ, Lavini C, van Linde ME, Stalpers LJ, Majoie CB, Reijneveld JC, van Furth WR, Richel DJ. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann Oncol 2010, 21(8):1723-1727. 10.1093/annonc/mdp591, 20064829.
38. Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S, McLendon RE, Herndon JE, Marcello JE, Norfleet J, Friedman AH, Bigner DD, Friedman HS. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer 2009, 101(12):1986-1994. 10.1038/sj.bjc.6605412, 2795427, 19920819.
39. Thompson EM, Dosa E, Kraemer DF, Neuwelt EA. Bevacizumab plus carboplatin increases survival in patients with recurrent malignant glioma [abstract]. Neuro Oncol 2009, 11(5):625-626.
40. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349(5):427-434. 10.1056/NEJMoa021491, 2275324, 12890841.
41. Semrad TJ, O'Donnell R, Wun T, Chew H, Harvey D, Zhou H, White RH. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 2007, 106(4):601-608. 10.3171/jns.2007.106.4.601, 17432710.
42. Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert MR, Mahankali S, Jackson EF, Levin VA, Conrad CA, Hsu SH, Colman H, de Groot JF, Ritterhouse MG, Ictech SE, Yung WK. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol 2008, 10(2):216-222. 10.1215/15228517-2007-060, 2613824, 18314417.
43. Fadul CE, Kingman LS, Meyer LP, Cole BF, Eskey CJ, Rhodes CH, Roberts DW, Newton HB, Pipas JM. A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. J Neurooncol 2008, 90(2):229-235. 10.1007/s11060-008-9655-9, 18661102.
44. Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 2007, 81(3):271-277. 10.1007/s11060-006-9225-y, 17031561.
45. Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, Figg WD, Purow BW, Borkowf CB. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 2003, 21(12):2299-2304. 10.1200/JCO.2003.08.045, 12805330.
46. Reardon D, Friedman H, Yung WKA, Brada M, Conrad C, Provenzale J, Jackson E, Serajuddin H, Chen B, Laurent D. A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM) [abstract]. Proc Am Soc Clin Oncol 2004, 22(14s):110s.
47. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356(2):115-124. 10.1056/NEJMoa065044, 17215529.
48. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007, 25(33):5165-5171. 10.1200/JCO.2007.11.5345, 18024863.
49. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009, 27(5):740-745. 10.1200/JCO.2008.16.3055, 2645088, 19114704.
50. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M, Nabors LB. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008, 26(34):5610-5617. 10.1200/JCO.2008.16.7510, 18981465.
51. Fink K, Mikkelsen T, Nabors LB, Ravin P, Plotkin SR, Schiff D, Hicking C, Picard M, Reardon DA. Long-term effects of cilengitide, a novel integrin inhibitor, in recurrent glioblastoma: A randomized phase IIa study [abstract]. J Clin Oncol 2010, 28(15 suppl):182s.
52. Wachsberger PR, Burd R, Cardi C, Thakur M, Daskalakis C, Holash J, Yancopoulos GD, Dicker AP. VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys 2007, 67(5):1526-1537. 10.1016/j.ijrobp.2006.11.011, 17234361.
53. De Groot JF, Wen PY, Lamborn K, Chang S, Cloughesy TF, Chen AP, DeAngelis LM, Mehta MP, Gilbert MR, Yung WK, Prados MD. Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601 [abstract]. J Clin Oncol 2008, 26(15 suppl):94s.
54. Wen PY, Prados M, Schiff D, Reardon DA, Cloughesy T, Mikkelsen T, Batchelor T, Drappatz J, Chamberlain MC, De Groot JF. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB) [abstract]. J Clin Oncol 2010, 28(15 suppl):181s.
55. Khasraw M, Abrey LE, Lassman AB, Hormigo A, Nolan C, Gavrilovic IT, Mellinghoff IK, Reiner AS, DeAngelis LM, AM Omuro AM. Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV) [abstract]. J Clin Oncol 2010, 28(15 suppl):196s.
56. Quant EC, Norden AD, Drappatz J, Muzikansky A, Doherty L, Lafrankie D, Ciampa A, Kesari S, Wen PY. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol 2009, 11(5):550-555. 10.1215/15228517-2009-006, 2765344, 19332770.
57. Scott BJ, Quant EC, McNamara MB, Ryg PA, Batchelor TT, Wen PY. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro Oncol 2010, 12(6):603-607. 10.1093/neuonc/nop073, 20156808.
58. Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, DeAngelis LM, Lassman AB. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009, 73(15):1200-1206. 10.1212/WNL.0b013e3181bc0184, 2839807, 19822869.
59. Torcuator RG, Thind R, Anderson J, Doyle T, Haythem A, Ryu S, Jain R, Mohan YS, Schultz L, Rosenblum ML, Mikkelsen T. The role of fractionated stereotactic radiosurgery for malignant gliomas that had progressed on bevacizumab [abstract]. Neuro Oncol 2009, 11(5):664.
60. Gerstner ER, Chen PJ, Wen PY, Jain RK, Batchelor TT, Sorensen G. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol 2010, 12(5):466-472.
61. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, Conrad CA. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010, 12(3):233-242.
62. Gruber ML, Kunnakkat S, Medabalmi P, Gruber DB, Golfinos J, Parker E, Narayana A. Change in pattern of relapse in newly diagnosed high-grade glioma following bevacizumab therapy [abstract]. J Clin Oncol 2010, 28(15 suppl):184s.
63. Platten M, Dörner N, Hofer S, Schäfer N, Schemmer D, Weller M, Bendszus M, Wick W, Wick A. Evaluation of distant spread in bevacizumab-treated versus control-treated patients with malignant gliomas: a matched-pair study [abstract]. J Clin Oncol 2010, 28(15 suppl):195s.
64. Pope WB, Xia Q, Das A, Hambleton J, Kim H, Brown M, Goldin J, Cloughesy TF. Patterns of progression in patients with glioblastoma at first or second relapse treated with bevacizumab alone or in combination with irinotecan in the BRAIN study [abstract]. Neuro Oncol 2009, 11(5):626.
65. Chamberlain M. Radiographic patterns of relapse in glioblastoma [abstract]. J Clin Oncol 2010, 28(15 suppl):185s.
66. Shapiro LQ, Karimi S, Gutin PH, Iwamoto FM, Zhang Z, Lassman AB, Abrey LE, Beal K. Patterns of failure following concurrent bevacizumab and hypofractionated stereotactic radiotherapy for recurrent high-grade glioma [abstract]. Int J Radiat Oncol Biol Phys 2009, 75(3 suppl):s125.
67. Chamberlain MC. Radiographic patterns of relapse in glioblastoma. J Neurooncol 2011, 101(2):319-323. 10.1007/s11060-010-0251-4, 21052776.
68. Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC, Pledger WJ, Jove R. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 2007, 67(6):2800-2808. 10.1158/0008-5472.CAN-06-3469, 17363602.
69. Lee C-G, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, Park KR, Ferrara N, Jain RK, Suit HD, Boucher Y. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000, 60(19):5565-5570.
70. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW, Weichselbaum RR. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999, 59(14):3374-3378.
71. Kermani P, Leclerc G, Martel R, Fareh J. Effect of ionizing radiation on thymidine uptake, differentiation, and VEGFR2 receptor expression in endothelial cells: the role of VEGF(165). Int J Radiat Oncol Biol Phys 2001, 50(1):213-220. 10.1016/S0360-3016(01)01445-6, 11316566.
72. Magnon C, Opolon P, Ricard M, Connault E, Ardouin P, Galaup A, Métivier D, Bidart JM, Germain S, Perricaudet M, Schlumberger M. Radiation and inhibition of angiogenesis by canstatin synergize to induce HIF-1alpha-mediated tumor apoptotic switch. J Clin Invest 2007, 117(7):1844-1855. 10.1172/JCI30269, 1884687, 17557121.
73. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6(6):553-563.
74. Ma BB, Bristow RG, Kim J, Siu LL. Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol 2003, 21(14):2760-2776. 10.1200/JCO.2003.10.044, 12860956.
75. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444(7120):756-760. 10.1038/nature05236, 17051156.
76. Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005, 23(31):8136-8139. 10.1200/JCO.2005.02.5635, 16258121.
77. Czito BG, Bendell JC, Willett CG, Morse MA, Blobe GC, Tyler DS, Thomas J, Ludwig KA, Mantyh CR, Ashton J, Yu D, Hurwitz HI. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: phase I trial results. Int J Radiat Oncol Biol Phys 2007, 68(2):472-478. 10.1016/j.ijrobp.2007.02.001, 17498568.
78. Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, Mischel P, Liau LM, Bergsneider M, Pope W, Selch M, Cloughesy T. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 2008, 71(5):1372-1380. 10.1016/j.ijrobp.2007.11.068, 18355978.
79. Narayana A, Golfinos JG, Fischer I, Raza S, Kelly P, Parker E, Knopp EA, Medabalmi P, Zagzag D, Eagan P, Gruber ML. Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys 2008, 72(2):383-389. 10.1016/j.ijrobp.2008.05.062, 18793954.
80. Lai A, Nghiemphu P, Green RM, Spier L, Peak S, Phuphanich S, Fehrenbacher L, Kolevska T, Polikoff JA, Cloughesy TF. Updated results of phase II trial of bevacizumab in combination with temozolomide and regional radiation therapy for upfront treatment of patients with newly diagnosed glioblastoma multiforme [abstract]. Neuro Oncol 2009, 11(5):632.
81. Nicholas MK, Lucas RV, Arzbaecher J, Paleologos N, Krouwer H, Malkin M, Omar A, Vick NA. Bevacizumab in combination with temozolomide in the adjuvant treatment of newly diagnosed glioblastoma multiforme: Preliminary results of a phase II study [abstract]. J Clin Oncol 2009, 27(15 suppl):91s.
82. Vredenburgh JJ, Desjardins A, Reardon DA, Peters K, Kirkpatrick J, Herndon JE, Marcello J, Bailey L, Threatt S, Friedman HS. Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM) [abstract]. J Clin Oncol 2010, 28(15 suppl):185s.
83. Omuro AM, Beal K, Karimi S, Chan TA, Panageas K, Nayak L, Seko B, DeAngelis LM, Abrey LE, Gutin PH. Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM) [abstract]. J Clin Oncol 2010, 28(15 suppl):188s.
84. Shih KC, Spigel DR, Burris III HA, Brown RH, Shepard GC, Hainsworth JD. Phase II trial of radiation therapy/temozolomide/bevacizumab followed by bevacizumab/everolimus in the first-line treatment of glioblastoma multiforme (GBM) [abstract]. J Clin Oncol 2010, 28(15 suppl):198s.
85. Hofland KF, Poulsen HS, Sørensen MP, Ask A, Bertelsen AK, Spahn-Horn S, Hansen S, Schulz HP, Lassen U. First-line therapy with bevacizumab and irinotecan versus bevacizumab and temozolomide and delayed concomitant radiotherapy in newly diagnosed primary glioblastoma multiforme: early results from a randomized phase II study [abstract]. Neuro Oncol 2009, 11(5):620.
86. van Linde ME, Verhoeff JJC, Stalpers LJA, Reijneveld JC, Richel DJ, Van Furth WR. Feasibility of combined treatment with bevacizumab, radiotherapy, and temozolomide in resectable and unresectable newly diagnosed glioblastoma multiforme [abstract]. Neuro Oncol 2009, 11(5):628.
87. Chinot O, de La Motte T, Zeaiter A, Moore N, Das A, Swamy R, Cloughesy TF. Preclinical and clinical rationale for a phase III trial of bevacizumab combined with the current standard of care in patients with newly diagnosed glioblastoma multiforme (ND-GBM) [abstract]. Neuro Oncol 2009, 11(5):628.
88. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M. Phase I/IIa trial of cilengitide and temozolomide with concomitant radiotherapy, followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010, 28(16):2712-2718. 10.1200/JCO.2009.26.6650, 20439646.
89. Brandes AA, Stupp R, Hau P, Lacombe D, Gorlia T, Tosoni A, Mirimanoff RO, Kros JM, van den Bent MJ. EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur J Cancer 2010, 46(2):348-354. 10.1016/j.ejca.2009.10.029, 19945857.
90. Drappatz J, Norden AD, Wong ET, Doherty LM, Lafrankie DC, Ciampa A, Kesari S, Sceppa C, Gerard M, Phan P, Schiff D, Batchelor TT, Ligon KL, Young G, Muzikansky A, Weiss SE, Wen PY. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys 2010, 78(1):85-90. 10.1016/j.ijrobp.2009.07.1741, 20137866.
91. Nabors LB, Fiveash JB, Markert JM, Kekan MS, Gillespie GY, Huang Z, Johnson MJ, Meleth S, Kuo H, Gladson CL, Fathallah-Shaykh HM. A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Arch Neurol 2010, 67(3):313-319. 10.1001/archneurol.2010.16, 20212229.
92. Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009, 75(1):156-163. 10.1016/j.ijrobp.2008.10.043, 19167838.
93. Niyazi M, Ganswindt U, Schwarz SB, Kreth FW, Tonn JC, Geisler J, la Fougère C, Ertl L, Linn J, Siefert A, Belka C. Irradiation and bevacizumab in high-grade glioma retreatment settings. Int J Radiat Oncol Biol Phys 2010,
94. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11(1):83-95. 10.1016/j.ccr.2006.11.021, 2748664, 17222792.
95. Gonzalez J, Kumar AJ, Conrad CA, Levin VA. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007, 67(2):323-326. 10.1016/j.ijrobp.2006.10.010, 17236958.
96. Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Prabhu S, Loghin M, Gilbert MR, Jackson EF. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2010,
97. Torcuator R, Zuniga R, Mohan YS, Rock J, Doyle T, Anderson J, Gutierrez J, Ryu S, Jain R, Rosenblum M, Mikkelsen T. Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol 2009, 94(1):63-68. 10.1007/s11060-009-9801-z, 19189055.
98. Desjardins A, Reardon DA, Herndon JE, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008, 14(21):7068-7073. 10.1158/1078-0432.CCR-08-0260, 18981004.
99. Kreisl TN, Butman JA, Hammoud D, Iwamoto FM, Kim L, Duic P, Albert P, Fine HA. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent anaplastic glioma [abstract]. Neuro Oncol 2009, 11(5):620.
100. Chamberlain MC, Johnston S. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer 2009, 115(8):1734-1743. 10.1002/cncr.24179, 19197992.
101. Chamberlain MC, Johnston S. Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol 2009, 91(3):359-367. 10.1007/s11060-008-9722-2, 18953491.
102. Gerstner ER, Chen Q, Batchelor T, Sorensen AG. Use of FLAIR MRI in determining glioblastoma response to cediranib [abstract]. J Clin Oncol 2010, 28(15 suppl):195s.
103. Chamberlain MC. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2009, 72(8):772-773. author reply 773-774., 10.1212/01.wnl.0000339387.03225.0a, 19237713.
104. Verhoeff JJ, van Tellingen O, Claes A, Stalpers LJ, van Linde ME, Richel DJ, Leenders WP, van Furth WR. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 2009, 9:444. 10.1186/1471-2407-9-444, 2801683, 20015387.
105. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: response assessment in Neuro-Oncology Working Group. J Clin Oncol 2010, 28(11):1963-1972. 10.1200/JCO.2009.26.3541, 20231676.
106. Gerstner ER, Frosch MP, Batchelor TT. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol 2010, 28(6):e91-e93. 10.1200/JCO.2009.25.0233, 19933906.
107. Ferl GZ, Xu L, Friesenhahn M, Bernstein LJ, Barboriak DP, Port RE. An automated method for nonparametric kinetic analysis of clinical DCE-MRI data: application to glioblastoma treated with bevacizumab. Magn Reson Med 2010, 63(5):1366-1375. 10.1002/mrm.22335, 20432307.
108. Sawlani RN, Raizer J, Horowitz SW, Shin W, Grimm SA, Chandler JP, Levy R, Getch C, Carroll TJ. Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging-pilot study. Radiology 2010, 255(2):622-628. 10.1148/radiol.10091341, 20413772.
109. Pope WB, Kim HJ, Huo J, Alger J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy T, Mischel PS, Lai A, Nghiemphu P, Rahmanuddin S, Goldin J. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009, 252(1):182-189. 10.1148/radiol.2521081534, 19561256.
110. Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Norfleet J, Gururangan S, Friedman HS, Reardon DA. Phase II trial of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: final results [abstract]. J Clin Oncol 2010, 28(15 suppl):193s.
111. Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sørensen M, Kosteljanetz M, Broholm H, Stockhausen MT, Poulsen HS. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol 2010, 12(5):508-516.
112. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010, 28(17):2817-2823. 10.1200/JCO.2009.26.3988, 20458050.
113. Schiff D, Reardon DA, Kesari S, Mikkelsen T, De Groot JF, Fichtel L, Coyle TE, Wong E, Eaton C, Silver B. Phase II study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma (rGBM) [abstract]. J Clin Oncol 2010, 28(15 suppl):182s.
114. US National Institutes of Health Clinicaltrials.gov Web site. , http://www.clinicaltrials.gov